QIAGEN and Natera Partner to Develop Cutting-Edge Genetic Testing Assays for Use on QIAGEN’s GeneReader NGS System
March 12 2018 - 4:00PM
Business Wire
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA), a world
leader in providing Sample to Insight molecular solutions, and
Natera, Inc. (NASDAQ: NTRA), a leading developer of next-generation
sequencing (NGS) assays that include non-invasive prenatal genetic
testing and the analysis of circulating tumor DNA, today announced
a partnership to develop cutting-edge cell-free DNA assays for use
on QIAGEN’s GeneReader NGS System.
These cell-free DNA assays will now be developed for use on the
GeneReader NGS System, the first fully integrated Sample to Insight
NGS solution, and designed to enable these type of tests, including
prenatal screening, for hospitals and laboratories globally.
Natera’s Constellation™ software would also be accessible for users
of these and other assays in combination with the QIAGEN Clinical
Insights (QCI) bioinformatics solution.
“We are excited to partner with Natera, a global market leader
in non-invasive cell-free DNA genetic testing. Through this
strategic partnership, we are planning to offer assays that provide
significant clinical and economic value backed by extensive
validation data and large clinical studies. We intend to make these
assays available on the GeneReader NGS System to laboratories
around the world that are very eager to bring in-house genetic
testing across several applications, including prenatal screening,”
said Peer M. Schatz, Chief Executive Officer of QIAGEN N.V. “The
addition of these assays, along with Natera’s Constellation
software, will substantially increase the system’s value and
utility for a broader range of customers beyond the current menu
focused on oncology.”
“This strategic partnership is an important milestone in the
development of Natera, and we welcome the opportunity to partner
with QIAGEN since both companies share a commitment to providing
customers with actionable and often life-changing clinical
insights,” said Matthew Rabinowitz, CEO of Natera. “We are
combining Natera’s molecular and clinical experience in NGS content
development with QIAGEN’s expertise in offering a complete and
integrated NGS workflow to offer Sample to Insight testing
leveraging Natera’s Constellation cloud platform. We also believe
the global reach of QIAGEN will help us capitalize on the emergence
and power of next-generation sequencing globally, and make these
assays broadly accessible to hospital systems and laboratories
worldwide.”
Please find the full press release here
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180312006130/en/
Natera:Investor RelationsMike Brophy, CFO, +1
650-249-9091 x 1471mbrophy@natera.comorMediaAnna Czene, PR,
+1 818-731-2203aczene@natera.comorQIAGEN:Investor
RelationsJohn Gilardi, +49 2103 29
11711ir@QIAGEN.comorPublic RelationsDr. Thomas Theuringer,
+49 2103 29 11826pr@QIAGEN.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024